- WuXi Biologics has launched WuXia293Stable, a HEK293-based platform for stable, high-quality expression of difficult-to-express molecules.
- The platform delivers up to 5.0 g/L titers and supports scalable manufacturing up to 2000L for fed-batch processes.
WuXi Biologics has announced the launch of WuXia293Stable, a new platform designed for the development and manufacturing of complex biologics that are stably expressed in HEK293 cells. The technology targets innovative, difficult-to-express molecules, offering high titers, robust stability, and improved purity.
Traditionally, CHO cells have been used for recombinant protein expression. However, some complex modalities face low yields or quality issues in CHO systems due to host cell proteins. According to the company, HEK293 cells can address these limitations by reducing truncation issues while maintaining high production levels.
WuXia293Stable is derived from WuXi Biologics’ proprietary HEK293 cell line and is part of the WuXia™ platform family. The platform delivers fed-batch titers of up to 5.0 g/L for monoclonal antibodies, with scalable manufacturing options up to 2000L for fed-batch and 1000L for perfusion processes. It also offers compatibility with existing WuXia™ processes, enabling streamlined development.
Service options for WuXia293Stable include cell bank testing and viral clearance validation, integrated into WuXi Biologics’ one-stop CMC offering. Other WuXia™ derivatives, such as WuXiaADCC Plus™ and WuXia RidGS™, address different client needs within the biologics development spectrum.
Dr. Chris Chen, CEO of WuXi Biologics, stated: “WuXia293Stable stands as a powerful testament to WuXi Biologics’ unwavering commitment to our vision that every biologic can be made and exemplifies our dedication to technological innovation, which enables us to adeptly address the evolving needs of the biopharmaceutical industry.”
